1-3 of 3
Vassilios Lougaris
Close
Sort by
Journal Articles

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome

Clinical Trials & Observations
V. Koneti Rao, Sharon Webster, Anna Šedivá, Alessandro Plebani, Catharina Schuetz, Anna Shcherbina, Niall Conlon, Tanya Coulter, Virgil A. Dalm, Antonino Trizzino, Yulia Zharankova, Elaine Kulm, Julia Körholz, Vassilios Lougaris, Yulia Rodina, Kath Radford, Jason Bradt, Klaus Kucher, Anurag Relan, Steven M. Holland, Michael J. Lenardo, Gulbu Uzel
Journal: Blood
Blood (2023) 141 (9): 971–983.
https://doi.org/10.1182/blood.2022018546
Published: 2023
Includes: Supplemental data
Journal Articles

Interim Analysis of Safety and Hematological Parameters of an Ongoing Long-Term Open-Label Extension Study of Investigational PI3Kδ Inhibitor Leniolisib for Patients with Activated PI3K Delta Syndrome (APDS) through December 2021

V. Koneti Rao, Sharon Webster, Anna Sediva, Alessandro Plebani, Catharina Schuetz, Anna Shcherbina, Virgil A.S.H. Dalm, Antonino Trizzino, Yulia Zharankova, Elaine Kulm, Alanvin Orpia, Lavenda Chirombo Kluczynski, Julia Körholz, Vassilios Lougaris, Yulia Rodina, Klaus Kucher, Kath Radford, Jason Bradt, Gulbu Uzel
Journal: Blood
Blood (2022) 140 (Supplement 1): 1643–1645.
https://doi.org/10.1182/blood-2022-160334
Published: 2022
Journal Articles

Defect of plasmacytoid dendritic cells in warts, hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome patients

Brief Report
Laura Tassone, Daniele Moratto, William Vermi, Maria De Francesco, Lucia D. Notarangelo, Fulvio Porta, Vassilios Lougaris, Fabio Facchetti, Alessandro Plebani, Raffaele Badolato
Journal: Blood
Blood (2010) 116 (23): 4870–4873.
https://doi.org/10.1182/blood-2010-03-272096
Published: 2010
Includes: Supplemental data